VGXI Breaks Ground for New Manufacturing Facility in Conroe, TX
Plasmid DNA Manufacturer VGXI, Inc. Breaks Ground for New Conroe-based Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, held a groundbreaking ceremony on November 10, 2020 for its new greenfield manufacturing facility. The milestone event was hosted by VGXI in accordance with CDC COVID-19… Read More »
VGXI Wins Best Contract Manufacturing Organization for the 2020 Vaccine Industry Excellence Awards
Texas-based plasmid DNA CDMO VGXI, Inc. was recognized as the winner of the 2020 ViE Award for Best Contract Manufacturing Organization at the World Vaccine Congress Washington. The Woodlands, TX – VGXI, Inc., a contract development and manufacturing organization specialized in production of pre-clinical through cGMP grade DNA-based biopharmaceuticals, announced it has been recognized as… Read More »
VGXI Completes Land Purchase and Advances Design Development for New Manufacturing Facility
Plasmid DNA Manufacturer VGXI, Inc. Completes Land Purchase and Proceeds with Design Development Phase for New Expanded Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has closed on the purchase of greenfield for a new, expanded manufacturing facility. The site is located… Read More »
VGXI’s Statement on the Recent Litigation Involving Inovio Pharmaceuticals, Inc. (“Inovio”) in Pennsylvania State Court
Update June 26, 2020: VGXI and GeneOne are pleased with the court’s decision in our favor protecting our company’s intellectual property rights. We have always been willing to manufacture any vaccine candidate for Covid-19, and want to help find a cure. Original Post on June 04, 2020: VGXI was surprised by Inovio’s court filing, as… Read More »
VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement. THE WOODLANDS,TX AND PLYMOUTH MEETING, PA – Leading plasmid DNA contract manufacturer VGXI, Inc. announced it has completed accelerated cGMP manufacturing of the first clinical batch of a personalized neoantigen vaccine for its client Geneos Therapeutics, Inc. Geneos… Read More »
Deison Technology Park Provides Increased Capacity for VGXI to Manufacture Vaccines
News article released this week by the Conroe Economic Development Council announced VGXI’s planned 240,000 square-foot facility to meet increasing demand for high quality plasmid DNA products and services http://www.conroeedc.org/deison-technology-park-provides-increased-capacity-for-vgxi/
VGXI Supports Rapid Timeline to Clinical Testing for Coronavirus Vaccine
Plasmid CDMO VGXI, Inc. Completes Manufacturing and Release of a Vaccine against COVID-19 in Record-Setting Time The Woodlands, TX – VGXI, an industry leading provider of GMP grade plasmid DNA for vaccines and gene therapies, announced it has completed manufacturing and release of a DNA vaccine to combat the COVID-19 pandemic. VGXI was selected by… Read More »
VGXI Recognized as Best CMO Finalist for the 2020
Texas-based plasmid DNA manufacturer VGXI, Inc. recognized as a finalist for Best CMO for the ViE Awards of the World Vaccine Congress The Woodlands, TX – VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of Best Contract Manufacturing… Read More »
VGXI to Exhibit at Gene Therapy for Rare Disorders
The 4th Annual Gene Therapy for Rare Disorders will focus on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Visit VGXI at Booth #6 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene therapy program! Contact… Read More »
VGXI to Exhibit at the 2020 World Vaccine Congress
The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #310 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! Each year at WVC the winners are announced for the annual… Read More »
VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration
Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV) that has recently… Read More »